Vaxcyte (PCVX) Share-based Compensation (2019 - 2026)

Vaxcyte (PCVX) has reported Share-based Compensation for 8 consecutive years, with $9.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Share-based Compensation rose 75.71% year-over-year to $9.3 million; the TTM figure through Mar 2026 stood at $15.0 million (down 79.31% YoY), while the FY2025 annual figure was $11.0 million, down 87.04% from the prior year.
• Share-based Compensation grew to $9.3 million in Q1 2026 per PCVX's latest filing, from -$91.9 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $96.8 million in Q3 2025 and bottomed at -$91.9 million in Q4 2025.
• Historically, Share-based Compensation has averaged $6.1 million across 5 years, with a median of $4.1 million in 2022.
• Annual changes were most pronounced in 2022 — Share-based Compensation slumped 749.65% — and 2024, when it surged 86478.31%.
• Vaxcyte's Share-based Compensation stood at -$15.8 million in 2022, then sank by 99.85% to -$31.5 million in 2023, then jumped by 327.09% to $71.6 million in 2024, then plunged by 228.27% to -$91.9 million in 2025, then soared by 110.12% to $9.3 million in 2026.
• Business Quant data shows PCVX's Share-based Compensation at $9.3 million in Q1 2026, -$91.9 million in Q4 2025, and $96.8 million in Q3 2025.